Halabi, Susan
Duke University · Duke Medical Center
8 papers on CoChatORCID 0000-0003-4135-2777
Most cited papers
- Verified
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer
Halabi, S., Kelly, W. K., Ma, H., Zhou, H., Solomon, N. C., Fizazi, K., Tangen, C. M., Rosenthal, M., Petrylak, D. P., Hussain, M., et al. (2016) · Journal of Clinical Oncology
Prostate Cancer Treatment and ResearchBone health and treatments
Cited by 461
- Verified
Circulating Levels of Inflammatory Cytokines and Risk of Colorectal Adenomas
Kim, S., Keku, T. O., Martin, C., Galanko, J., Woosley, J. T., Schroeder, J. C., Satia, J. A., Halabi, S., & Sandler, R. S. (2008) · Cancer Research
Adipokines, Inflammation, and Metabolic DiseasesColorectal Cancer Screening and Detection
Cited by 298
- Verified
Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021
Gillessen, S., Armstrong, A., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R. G., Bulbul, M., et al. (2022) · European Urology
Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment
Cited by 130
- Verified
Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Al Baghdadi, T., Halabi, S., Garrett-Mayer, E., Mangat, P. K., Ahn, E. R., Sahai, V., Alvarez, R. H., Kim, E. S., Yost, K. J., Rygiel, A. L., et al. (2019) · JCO Precision Oncology
Pancreatic and Hepatic Oncology ResearchAdvanced Breast Cancer Therapies
Cited by 94
- Verified
ESMO guidance on the use of Large Language Models in Clinical Practice (ELCAP)
Wong, E. Y. T., Verlingue, L., Aldea, M., Franzoi, M. A., Umeton, R., Halabi, S., Harbeck, N., Indini, A., Prelaj, A., Romano, E., et al. (2025) · Annals of Oncology
Artificial Intelligence in Healthcare and EducationElectronic Health Records Systems
Cited by 44
- Verified
Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study.
Gupta, R., Garrett-Mayer, E., Halabi, S., Mangat, P. K., D'Andre, S. D., Meiri, E., Shrestha, S., Warren, S. L., Ranasinghe, S., & Schilsky, R. L. (2020) · Journal of Clinical Oncology
Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research
Cited by 41
- Verified
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
Halabi, S., Yang, Q., Roy, A., Luo, B., Araujo, J. C., Logothetis, C., Sternberg, C. N., Armstrong, A. J., Carducci, M. A., Chi, K. N., et al. (2023) · Journal of Clinical Oncology
Prostate Cancer Treatment and ResearchBone health and treatments
Cited by 30
- Verified
9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901
Amin, A., Halabi, S., Gelmann, E. P., Stadler, W., Vogelzang, N., & Small, E. (2004) · Urologic Oncology: Seminars and Original Investigations
Prostate Cancer Treatment and ResearchCancer therapeutics and mechanisms
Cited by 9
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free